Myeloperoxidase: New roles for an old molecule

Journal of Medical Biochemistry

Volumn 30, Issue 3, 2011, Pages 230-236

  Stanković, Sanja ^a   Majkić Singh, Nada ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

acute coronary syndrome; chest pain; inflammation; myeloperoxidase

Indexed keywords

MYELOPEROXIDASE; PEROXIDASE; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE;

ACUTE CORONARY SYNDROME; ARTICLE; CARDIOVASCULAR DISEASE; ENZYME ACTIVITY; ENZYME SYNTHESIS; HUMAN; INFLAMMATION; LEUKOCYTE; MONOCYTE; NEUTROPHIL; PROTEIN EXPRESSION; PROTEIN PROCESSING; RISK ASSESSMENT; THORAX PAIN; TISSUE INJURY;

EID: 79959564184     PISSN: 14528258     EISSN: 14528266     Source Type: Journal    
DOI: 10.2478/v10011-011-0033-3     Document Type: Article

References (54)

1. Agner K. Verdoperoxidase. A ferment isolated from leucocytes. Acta Physiol Scand 1941; 2 (Suppl. 8): 1-62.
2. Bos A, Wever R, Roos D. Characterization and quantification of the peroxidase in human monocytes. Biochim Biophys Acta 1978; 525: 37-44. (Pubitemid 8370729)
3. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myelo -peroxidase, a catalyst for lipoprotein oxidation, is ex -pressed in human atherosclerotic lesions. J Clin Invest 1994; 94: 437-44. (Pubitemid 24218123)
4. Hansson M, Olsson I, Nauseef WM. Biosynthesis, processing, and sorting of human myeloperoxidase. Arch Biochem Biophys 2006; 445: 214-24. (Pubitemid 43082214)
5. Chevrier I, Tregouet DA, Massonnet-Castel S, Beaune P, Loriot MA. Myeloperoxidase genetic polymorphisms mo -dulate human neutrophil enzyme activity: genetic determinants for atherosclerosis? Atherosclerosis 2006; 188: 150-4. (Pubitemid 44142532)
6. Hoy A, Tregouet D, Leininger-Muller B, Poirier O, Ma u -rice M, Sass C, et al. Serum myeloperoxidase concentration in a healthy population: biological variations, fa milial resemblance and new genetic polymorphisms. Eur J Hum Genet 2001; 9: 780-6. (Pubitemid 33014591)
7. Nikpoor B, Turecki G, Fournier C, Theroux P, Rouleau GA. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Ca -nadians. Am Heart J 2001; 142: 336-9. (Pubitemid 32706293)
8. Makela R, Laaksonen R, Janatuinen T, Vesalainen R, Nuutila P, Jaakola O, et al. Myeloperoxidase gene variation and coronary flow reserve in young healthy men. J Biomed Sci 2004; 11: 59-64. (Pubitemid 38142353)
9. Pecoits-Filho R, Stenvinkel P, Marchlewska A, et al. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal dis-ease patients. Kidney Int Suppl 2003; S172-6. (Pubitemid 36513403)
10. Asselbergs FW, Reynolds WF, Cohen-Tervaert JW, Jessurun GA, Tio RA. Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. Am J Med 2004; 116: 429-30. (Pubitemid 38299491)
11. Wainstein RV, Wainstein MV, Ribeiro JP, et al. Association between myeloperoxidase polymorphisms and its plasma levels with severity of coronary artery disease. Clin Bio -chem 2010; 43: 57-62.
12. Domigan NM, Charlton TS, Duncan MW, Winterbourn CC, Kettle AJ. Chlorination of tyrosyl residues in peptides by myeloperoxidase and human neutrophils. J Biol Chem 1995; 270: 16542-8.
13. Hazen SL, Hsu FF, Mueller DM, Crowley JR, Heinecke JW. Human neutrophils employ chlorine gas as an oxidant during phagocytosis. J Clin Invest 1996; 98: 1283-9. (Pubitemid 26322052)
14. Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, Halliwell B, Van der Vliet A. Formation of nitric oxidederived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 1998; 391: 393-7. (Pubitemid 28093514)
15. Gaut JP, Byun J, Tran HD, Lauber WM, Carroll JA, Hotchkiss RS, Belaaouaj A, Heinecke JW. Myelo per -oxidase produces nitrating oxidants in vivo. J Clin Invest 2002; 109: 1311-19. (Pubitemid 34546895)
16. Hazen SL, Heinecke JW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is mar -kedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 1997; 99: 2075-81. (Pubitemid 27203762)
17. Leeuwenburgh C, Rasmussen JE, Hsu FF, Mueller DM, Pennathur S, Heinecke JW. Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. J Biol Chem 1997; 272: 3520-6. (Pubitemid 27066853)
18. Podrez EA, Febbraio M, Sheibani N, Schmitt D, Silverstein RL, Hajjar DP, Cohen PA, Frazier WA, Hoff HF, Hazen SL. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-ge -nerated reactive nitrogen species. J Clin Invest 2000; 105: 1095-108. (Pubitemid 30217694)
19. Shao B, Oda MN, Oram JF, Heinecke JW. Myeloper -oxidase: an oxidative pathway for generating dysfunc - tio nal high-density lipoprotein. Chem Res Toxicol 2010; 23: 447-54.
20. Wever RMF, Luscher TF, Cosentino F, Rabelink TJ. Athe -rosclerosis and the two faces of endothelial nitric oxide synthase. Circulation 1998; 97: 108-12. (Pubitemid 28036161)
21. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A, et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 2002; 296: 2391-4. (Pubitemid 34734213)
22. Fu X, Kassim SY, Parks WC, Heinecke JW. Hypochlorous acid oxygenates the cysteine switch domain of promatrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 2001; 276: 41279-87.
23. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in hu -man atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001; 158: 879-91. (Pubitemid 32221781)
24. Baldus S, Eiserich JP, Mani A, Castro L, Figueroa M, Chumley P, et al. Endothelial transcytosis of myeloper -oxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J Clin Invest 2001; 108: 1759-70. (Pubitemid 34015121)
25. Sugiyama S, Kugiyama K, Aikawa M, Nakamura S, Ogawa H, Libby P. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterio -scler Thromb Vasc Biol 2004; 24: 1309-14. (Pubitemid 38880026)
26. Meuwese MC, Stroes ES, Hazen SL, Van Miert JN, Kuivenhoven JA, Schaub RG, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPICNorfolk Prospective Population Study. J Am Coll Cardiol 2007; 50: 159-65. (Pubitemid 47002189)
27. Wong ND, Gransar H, Narula J, Shaw L, Moon JH, Miranda-Peats R, et al. Myeloperoxidase, subclinical athe rosclerosis, and cardiovascular disease events. JACC Cardiovasc Imaging 2009; 2: 1093-9.
28. Brennan ML, Penn MS, Van Lente F, Nambi V, Shisheh -bor MH, Aviles RJ, et al. Prognostic value of myeloper -oxidase in patients with chest pain. N Engl J Med 2003; 349: 1595-604. (Pubitemid 37288567)
29. Rudolph V, Goldmann BU, Bos C, Rudolph TK, Klinke A, Friedrichs K, et al. Diagnostic value of MPO plasma le vels in patients admitted for suspected myocardial infarction. Int J Cardiol 2010 Sep 14.
30. Apple FS, Pearce LA, Chung A, Ler R, Murakami MM. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem 2007; 53: 874-81. (Pubitemid 46744243)
31. Apple FS, Smith SW, Pearce LA, Murakami MM. Assessment of the multiple-biomarker approach for diagnosis of myocardial infarction in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem 2009; 55: 93-100.
32. Cheng ML, Chen CM, Gu PW, Ho HY, Chiu DT. Elevated levels of myeloperoxidase, white blood cell count and 3-chlorotyrosine in Taiwanese patients with acute myo -cardial infarction. Clin Biochem 2008; 41: 554-60.
33. Esporcatte R, Rey HC, Rangel FO, Rocha RM, Mendona Filho HT, Dohmann HF, Albanesi Filho FM. Predictive value of myeloperoxidase to identify high risk patients admitted to the hospital with acute chest pain. Arq Bras Cardiol 2007; 89: 377-84.
34. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001; 286: 2136-42. (Pubitemid 34041599)
35. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circu -lation 2003; 108: 1440-5. (Pubitemid 37176448)
36. Exner M, Minar E, Mlekusch W, Sabeti S, Amighi J, Lalo -uschek W, et al. Myeloperoxidase predicts progression of carotid stenosis in states of low high-density lipoprotein cholesterol. J Am Coll Cardiol 2006; 47: 2212-18. (Pubitemid 43795075)
37. Cavusoglu E, Ruwende C, Eng C, Chopra V, Yanamadala S, Clark LT, et al. Usefulness of baseline plasma mye lo -peroxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol 2007; 99: 1364-8. (Pubitemid 46686633)
38. Mocatta TJ, Pilbrow AP, Cameron VA, Senthilmohan R, Frampton CM, Richards AM, Winterbourn CC. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol 2007; 49: 1993-2000. (Pubitemid 46734639)
39. Khan SQ, Kelly D, Quinn P, Davies JE, Ng LL. Mye -loperoxidase aids prognostication together with N-ter -minal pro-B-type natriuretic peptide in high-risk patients with acute ST elevation myocardial infarction. Heart 2007; 93: 826-31. (Pubitemid 46998982)
40. Morrow DA, Sabatine MS, Brennan ML, De Lemos JA, Murphy SA, Ruff CT, et al. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myelo -peroxidase and soluble CD40 ligand and the risk of re -current ischaemic events in TACTICS-TIMI 18. Eur Heart J 2008; 29: 1096-102. (Pubitemid 351844877)
41. Dominguez-Rodriguez A, Samimi-Fard S, Abreu-Gon -zalez P, Garcia-Gonzalez MJ, Kaski JC. Prognostic value of admission myeloperoxidase levels in patients with ST-segment elevation myocardial infarction and cardiogenic shock. Am J Cardiol 2008; 101: 1537-40.
42. Karadag B, Vatan B, Hacioglu Y, Duman D, Baskurt M, Keles I, et al. Serum myeloperoxidase level predicts reperfusion in patients with myocardial infarction receiving thrombolytic therapy. Heart Vessels 2009; 24: 247-53.
43. Borges FK, Borges FK, Stella FS, et al. Serial analysis of C-reactive protein and myeloperoxidase in acute coronary syndrome. Clin Cardiol 2009; 32: E58-62.
44. Chang LT, Chua S, Sheu JJ, Wu CJ, Yeh KH, Yang CH, Yip HK. Level and prognostic value of serum myeloperoxidase in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ J 2009; 73: 726-31.
45. Yunoki K, Naruko T, Komatsu R, Shirai N, Nakagawa M, Sugioka K, et al. Relation of elevated levels of plasma myeloperoxidase to impaired myocardial microcirculation after reperfusion in patients with acute myocardial infarction. Am J Cardiol 2010; 105: 922-9.
46. Roman RM, Camargo PV, Borges FK, Rossini AP, Po -lanczyk CA. Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients. Coron Artery Dis 2010; 21: 129-36.
47. Duzguncinar O, Yavuz B, Hazirolan T, Deniz A, Tok -gozoglu SL, Akata D, Demirpence E. Plasma myeloperoxidase is related to the severity of coronary artery disease. Acta Cardiol 2008; 63: 147-52. (Pubitemid 351548698)
48. Ndrepepa G, Braun S, Mehilli J, Von Beckerath N, Schomig A, Kastrati A. Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. Eur J Clin Invest 2008; 38: 90-6. (Pubitemid 351143413)
49. Tang WH, Wu Y, Nicholls SJ, Hazen SL. Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease. Clin Chem 2011;57: 33-9.
50. Stefanescu A, Braun S, Ndrepepa G, Koppara T, Pavaci H, Mehilli J, et al. Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. Am Heart J 2008; 155: 356-60.
51. El Bejjani D, Hazen SL, Mackay W, Glass NE, Hulgan T, Tungsiripat M, McComsey GA. Higher plasma myeloperoxidase levels are not associated with an increased risk for cardiovascular events in HIV-infected adults. HIV Clin Trials 2008; 9: 207-11. (Pubitemid 351892875)
52. Kubala L, Lu G, Baldus S, Berglund L, Eiserich JP. Plasma levels of myeloperoxidase are not elevated in patients with stable coronary artery disease. Clin Chim Acta 2008; 394: 59-62.
53. Dominguez-Rodriguez A, Abreu-Gonzalez P, Kaski JC. Diurnal variation of circulating myeloperoxidase levels in patients with ST-segment elevation myocardial infarction. Int J Cardiol 2010; 144: 407-9.
54. Zelzer S, Khoschsorur G, Stettin M, Weihrauch G, Truschnig-Wilders M. Determination of myeloperoxidase in EDTA plasma: comparison of an enzyme-linked immunosorbent assay with a chemiluminescent automated immunoassay. Clin Chim Acta 2009; 406: 62-5.